comparemela.com

Latest Breaking News On - Jeffrey freedman - Page 9 : comparemela.com

Pharnext Provides an Update on its Pivotal Clinical Development Program in Charcot-Marie-Tooth Disease Type 1A ('CMT1A')

Pharnext Provides an Update on its Pivotal Clinical Development Program in Charcot-Marie-Tooth Disease Type 1A ('CMT1A')
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Schwann
Baden-wuberg
Germany
United-states
Paris
France-general
France
French
Pharnext
Pivotal-clinical-development-program-in-disease-type
Drug-administration
Euronext-growth-stock-exchange

Pharnext Provides an Update on its Pivotal -2-

Pharnext Provides an Update on its Pivotal -2-
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Schwann
Baden-wuberg
Germany
United-states
Paris
France-general
France
French
Mary-jane-elliott
Pharnext
Pivotal-clinical-development-program-in-disease-type
Drug-administration

AB Science announces that a new independent publication confirms that masitinib has anti-vital ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. AB Science announces that a new independent publication confirms that masitinib has anti-vital . AB ScienceJanuary 25, 2021 GMT NEW INDEPENDENT PUBLICATION CONFIRMS THAT MASITINIB HAS ANTI-VIRAL ACTIVITY AGAINST THE SARS-COV-2 VIRUS IN VITRO AND IS A PROMISING CANDIDATE FOR TREATING COVID-19 Paris, 25 January 2021, 8.30am CET AB Science SA (NYSE Euronext - FR0010557264 - AB) today announced the publication of preclinical study results with masitinib in COVID-19. Research led by scientists from the Institute of Human Virology (Guangzhou, China) has been published in the peer-reviewed journal mBIO (a journal of the American Society for Microbiology). The article, entitled ‘Engineering a reliable and convenient SARS-CoV-2 replicon system for analysis of viral RNA synthesis and screening of antiviral inhibitors’,[1] is freely accessible online from the mBio journal site https://mb

China
Guangzhou
Guangdong
United-states
Paris
France-general
France
French
American
Arthur-rouill
Jeffrey-freedman
Savas-tay

Organicell Regenerative Medicine, Inc. Becomes Current with SEC Reporting Requirements

Organicell Regenerative Medicine, Inc. (OTCBB: BPSR) (the “ Company”), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that it is now current in its SEC reporting requirements under the Securities Exchange Act of 1934, as amended (the “ Exchange Act”). Upon filing is Quarterly Report on Form 10-Q for the Quarter ended July 31, 2020 on December 18, 2020, the Company became current in its SEC reporting requirements under the Exchange Act. The Company had not been current in such filings since the filing of its Quarterly Report on Form 10-Q for the Quarter ended July 31, 2017. The Company’s periodic filings with the SEC under the Exchange Act may be reviewed online at the SEC’s website, www.sec.gov.

Florida
United-states
Maria-ines-mitrani
Jeffrey-freedman
Albert-mitrani
Organicell-regenerative-medicine-inc
Securities-exchange
Organicell-regenerative-medicine
Securities-exchange-act
Quarterly-report
Exchange-act
Regenerative-medicine

Organicell Regenerative Medicine, Inc. Becomes Current with SEC Reporting Requirements - Press Release

Organicell Regenerative Medicine, Inc. Becomes Current with SEC Reporting Requirements - Press Release
digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.

Florida
United-states
Maria-ines-mitrani
Jeffrey-freedman
Albert-mitrani
Organicell-regenerative-medicine-inc
Securities-exchange
Business-wire
Organicell-regenerative-medicine
Securities-exchange-act
Quarterly-report
Exchange-act

vimarsana © 2020. All Rights Reserved.